There were 1,659 press releases posted in the last 24 hours and 413,679 in the last 365 days.

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference

OXFORD, United Kingdom, June 15, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (“Summit”, or the “Company”) (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Glyn Edwards, CEO of Summit, will participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference on 21 June 2017 at 8:30am EDT in New York City.

In addition, Summit will hold one-on-one meetings at the conference. There will be no webcast of the panel.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office) 
Tel: +44 (0)1235 443 951
  +1 617 225 4455
   
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson 
 
Tel: +44 (0)20 7213 0880
   
N+1 Singer
(Broker)
Aubrey Powell / Lauren Kettle   
 
Tel: +44 (0)20 7496 3000
   
MacDougall Biomedical Communications
(US media contact)
Karen Sharma
Tel: +1 781 235 3060
ksharma@macbiocom.com
   
Consilium Strategic Communications
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-

Primary Logo